SG Americas Securities LLC Invests $893,000 in Twist Bioscience Corporation (NASDAQ:TWST)

SG Americas Securities LLC acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 22,751 shares of the company’s stock, valued at approximately $893,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in Twist Bioscience by 547.2% during the 1st quarter. Versant Capital Management Inc now owns 686 shares of the company’s stock valued at $27,000 after buying an additional 580 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after buying an additional 267 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after buying an additional 303 shares in the last quarter. Banque Transatlantique SA bought a new stake in Twist Bioscience during the 4th quarter valued at about $43,000. Finally, GF Fund Management CO. LTD. bought a new stake in Twist Bioscience during the 4th quarter valued at about $58,000.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Barclays decreased their price objective on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, April 10th. Guggenheim restated a “buy” rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price target on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. Finally, Robert W. Baird reduced their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $50.40.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 5,042 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total transaction of $189,831.30. Following the sale, the chief executive officer now owns 655,432 shares of the company’s stock, valued at approximately $24,677,014.80. The trade was a 0.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Paula Green sold 1,101 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $41,452.65. Following the sale, the senior vice president now directly owns 129,380 shares in the company, valued at approximately $4,871,157. This represents a 0.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 20,673 shares of company stock valued at $720,412 in the last 90 days. Insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Up 5.8%

Shares of Twist Bioscience stock opened at $35.89 on Thursday. The firm’s 50 day moving average price is $33.83 and its 200-day moving average price is $41.33. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 52-week low of $27.12 and a 52-week high of $60.90. The company has a market cap of $2.15 billion, a P/E ratio of -11.04 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The firm had revenue of $92.79 million during the quarter, compared to analysts’ expectations of $92.00 million. On average, sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.